Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4361175 | 0.96 | CALCRL (0.70) | CALCRLCYP3A4 | |
| SCHEMBL3960816 | 0.96 | CALCRL (0.70) | CALCRLCYP3A4 | |
| SCHEMBL4482842 | 0.92 | CALCRL (0.64) | CALCRLCYP3A4 | |
| SCHEMBL13331851 | 0.90 | CALCRL (0.63) | CALCRLCYP3A4 | |
| SCHEMBL13713009 | 0.90 | CALCRL (0.63) | CALCRLCYP3A4 | |
| SCHEMBL3962408 | 0.90 | CALCRL (0.80) | CALCRLCYP3A4 | |
| SCHEMBL3962499 | 0.90 | CALCRL (0.80) | CALCRLCYP3A4 | |
| SCHEMBL13331862 | 0.89 | CALCRL (0.62) | CALCRLCYP3A4 | |
| SCHEMBL13713280 | 0.89 | CALCRL (0.62) | CALCRLCYP3A4 | |
| SCHEMBL3962392 | 0.89 | CALCRL (0.79) | CALCRLCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638625-B2 | Crystalline compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-29 | — | — | US | claimed |
| US-20080086003-A1 | 1-[4-amino-3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine-p-toluenesulphonate or other inorganic organic salts; calcitonin gene related peptide-antagonist; useful for treating headache and migraine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-10 | — | — | US | claimed |
| US-7638625-B2 | Crystalline compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-29 | — | — | US | disclosed |
| US-20080086003-A1 | 1-[4-amino-3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine-p-toluenesulphonate or other inorganic organic salts; calcitonin gene related peptide-antagonist; useful for treating headache and migraine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080086003-A1 | 1-[4-amino-3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine-p-toluenesulphonate or other inorganic organic salts; calcitonin gene related peptide-antagonist; useful for treating headache and migraine | SUCNR1, TRPC1, TRPV1 | CALCRL 10/4885CYP3A4 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.